Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Copy Number Analysis in Congenital Nevi: Concordance and Diagnostic Limitations of aCGH, sWGS, and Methylation Sequencing.

Pigment cell & melanoma research·2026
Same author

Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice-an European Cooperative Study Group for Paediatric Rare Tumours survey.

European journal of endocrinology·2026
Same author

European Standard Clinical Practice Recommendations for Cutaneous Melanoma in Children and Adolescents.

Pediatric blood & cancer·2026
Same author

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents.

Pediatric blood & cancer·2026
Same author

Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations.

Pediatric blood & cancer·2026
Same author

Cognitive function in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.

Journal of neurology·2026

Related Experiment Video

Updated: Jul 14, 2026

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

Bright light therapy in Parkinson's disease: a pilot study.

Sebastian Paus1, Tanja Schmitz-Hübsch1, Ullrich Wüllner1

  • 1Department of Neurology, University of Bonn, Bonn, Germany.

Movement Disorders : Official Journal of the Movement Disorder Society
|May 23, 2007
PubMed
Summary

Bright light therapy (BLT) may improve motor symptoms and depression in Parkinson's disease (PD) patients by suppressing melatonin. This study found BLT beneficial, warranting further investigation in larger patient groups.

More Related Videos

A Protocol for Transcranial Photobiomodulation Therapy in Mice
13:07

A Protocol for Transcranial Photobiomodulation Therapy in Mice

Published on: November 18, 2018

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Related Experiment Videos

Last Updated: Jul 14, 2026

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

A Protocol for Transcranial Photobiomodulation Therapy in Mice
13:07

A Protocol for Transcranial Photobiomodulation Therapy in Mice

Published on: November 18, 2018

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Area of Science:

  • Neurology
  • Chronobiology
  • Sleep Medicine

Background:

  • Melatonin antagonism shows potential for Parkinson's disease (PD).
  • Bright light therapy (BLT), known to suppress melatonin, is used for depression and sleep issues but not yet studied in PD.
  • PD patients often experience motor symptoms, depression, and sleep disturbances.

Purpose of the Study:

  • To investigate the effects of BLT on motor symptoms, depression, and sleep in Parkinson's disease patients.
  • To evaluate BLT as a potential non-pharmacological intervention for PD management.

Main Methods:

  • A randomized, placebo-controlled, double-blind study was conducted on 36 PD patients.
  • Patients received 15 days of daily morning BLT (30 min) at either 7,500 lux (active) or 950 lux (placebo).
  • Assessments included the Parkinson's Disease Rating Scale (UPDRS) I-IV, Beck's Depression Inventory, and Epworth Sleepiness Scale.

Main Results:

  • The active BLT group showed significant improvements in tremor, UPDRS I, II, and IV scores, and depression.
  • No significant improvements were observed in the placebo group.
  • BLT was well-tolerated by all participants.

Conclusions:

  • Bright light therapy demonstrates potential as an effective and safe adjunctive treatment for motor symptoms and depression in Parkinson's disease.
  • Further research with larger cohorts and longer treatment durations is recommended for advanced PD patient populations.